Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.

Kreth S, Limbeck E, Hinske LC, Schütz SV, Thon N, Hoefig K, Egensperger R, Kreth FW.

Acta Neuropathol. 2013 May;125(5):671-81. doi: 10.1007/s00401-013-1081-1. Epub 2013 Jan 23.

PMID:
23340988
2.

Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.

Ramakrishnan V, Kushwaha D, Koay DC, Reddy H, Mao Y, Zhou L, Ng K, Zinn P, Carter B, Chen CC.

Cancer Biomark. 2011-2012;10(3-4):185-93. doi: 10.3233/CBM-2012-0245.

PMID:
22674304
3.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

4.

[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].

Zheng CQ, Ji SP, Gong F, Li AM, Tai JL, Zhang YP.

Ai Zheng. 2009 Jun;28(6):575-80. Chinese.

PMID:
19635193
5.

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J.

Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28.

PMID:
23715499
6.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

7.

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.

Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC.

Neuro Oncol. 2012 Jun;14(6):712-9. doi: 10.1093/neuonc/nos089. Epub 2012 May 8.

8.

A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas.

Kushwaha D, Ramakrishnan V, Ng K, Steed T, Nguyen T, Futalan D, Akers JC, Sarkaria J, Jiang T, Chowdhury D, Carter BS, Chen CC.

Oncotarget. 2014 Jun 30;5(12):4026-39.

9.

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR.

J Clin Oncol. 2008 Sep 1;26(25):4189-99. doi: 10.1200/JCO.2007.11.5964. Review.

10.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
11.

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC; German Glioma Network.

Int J Cancer. 2011 Aug 1;129(3):659-70. doi: 10.1002/ijc.26083.

12.

miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.

Khalil S, Fabbri E, Santangelo A, Bezzerri V, Cantù C, Di Gennaro G, Finotti A, Ghimenton C, Eccher A, Dechecchi M, Scarpa A, Hirshman B, Chen C, Ferracin M, Negrini M, Gambari R, Cabrini G.

Oncotarget. 2016 May 10;7(19):28195-206. doi: 10.18632/oncotarget.8618.

13.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

14.

Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Morandi L, Franceschi E, de Biase D, Marucci G, Tosoni A, Ermani M, Pession A, Tallini G, Brandes A.

BMC Cancer. 2010 Feb 18;10:48. doi: 10.1186/1471-2407-10-48.

15.

Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.

Fukushima T, Takeshima H, Kataoka H.

Anticancer Res. 2009 Nov;29(11):4845-54. Review.

16.

Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.

Berthois Y, Delfino C, Metellus P, Fina F, Nanni-Metellus I, Al Aswy H, Pirisi V, Ouafik L, Boudouresque F.

Cancer Biol Ther. 2014 Jul;15(7):938-50. doi: 10.4161/cbt.28920. Epub 2014 Apr 22.

17.

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.

J Neurochem. 2006 Feb;96(3):766-76. Epub 2006 Jan 9.

18.

Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.

Kishida Y, Natsume A, Toda H, Toi Y, Motomura K, Koyama H, Matsuda K, Nakayama O, Sato M, Suzuki M, Kondo Y, Wakabayashi T.

Tumour Biol. 2012 Apr;33(2):373-81. doi: 10.1007/s13277-012-0319-1. Epub 2012 Jan 26.

PMID:
22274924
19.

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaña C, Sanchez-Cespedes M, García-Villanueva M, Arribas L, Esteller M.

Clin Cancer Res. 2004 Aug 1;10(15):4933-8.

20.

Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.

Kewitz S, Stiefel M, Kramm CM, Staege MS.

Leuk Res. 2014 Jan;38(1):138-43. doi: 10.1016/j.leukres.2013.11.001. Epub 2013 Nov 13.

PMID:
24284332

Supplemental Content

Support Center